BioSig Advances Collaboration on Machine Learning and Artificial Intelligence Solutions for Healthcare
June 27 2023 - 8:30AM
BioSig Technologies, Inc. (NASDAQ: BSGM) (“BioSig” or the
“Company”), a medical technology company delivering unprecedented
accuracy and precision to intracardiac signal visualization, today
announced that it is advancing the research and development of an
artificial intelligence (AI) medical device platform in
collaboration with technical advisory partner Reified Labs.
The platform’s foundational machine learning model is
anticipated to be based on integrated healthcare datasets,
beginning with ECG and IECG data acquired by BioSig’s first
product, the PURE EP™ Platform. Electrophysiology-focused
technological solutions developed under the terms of the
collaboration may be integrated into PURE EP™ technology for
potential commercial application.
Cambridge, Massachusetts-based Reified Labs, a provider of
advanced artificial intelligence-focused technical advisory
services to the life sciences industry, is led by Harvard- and
MIT-trained Dr. Alexander D. Wissner-Gross, an award-winning
computer scientist, physicist, entrepreneur, and author. BioSig's
prior collaboration with Reified, established in 2019, has
yielded multiple patent applications1 and a research
publication2 on initial discoveries in AI-enhanced
electrocardiogram lead placement mapping.
On June 20, 2023, Dr. Wissner-Gross delivered a keynote address
at a prominent gathering of clinical leaders in Rochester,
Minnesota, exploring the exciting possibilities that artificial
intelligence brings to healthcare. In his speech, entitled
“Unsupervised Medicine: The Next Wave of AI in Healthcare,” Dr.
Wissner-Gross reviewed recent research advances in unsupervised (or
self-supervised) machine learning models. Such models appear to
have dramatically accelerated overall progress toward artificial
general intelligence (AGI), with one community forecast of the
expected arrival date of AGI collapsing from 2043 to 2026 in the
past two years alone. In describing AGI and how its applications
can be accelerated in healthcare, Dr. Wissner-Gross used Reified’s
prior collaboration with BioSig as a case study.
“The cutting-edge work this collaboration started in early 2019
to lay a foundation in AI was ahead of the curve, and our initial
findings may have several potentially valuable clinical
applications worthy of further exploration,” commented Kenneth
L. Londoner, Chairman and CEO of BioSig Technologies, Inc.
“The application of AGI and digital signal processing to
analyzing signals from the so-called human ‘electrome’ – the set of
all electrical and ionic currents in the human body – continues to
present a promising opportunity for realizing key medical advances
relating to disorders of the peripheral nervous system,” said Dr.
Wissner-Gross. “We look forward to our forthcoming collaboration
with BioSig.”
About BioSig TechnologiesBioSig
Technologies is an advanced medical technology company
bringing never-before-seen insights to the treatment of
cardiovascular arrhythmias. Through collaboration with physicians,
experts, and healthcare leaders across the field of
electrophysiology (EP), BioSig is committed to addressing
healthcare’s biggest priorities—saving time, saving costs, and
saving lives.
The Company’s first product, the PURE EP™ Platform, an FDA
510(k) cleared non-invasive class II device, provides superior,
real-time signal visualization allowing physicians to perform
insight-based, highly targeted cardiac ablation procedures with
increased procedural efficiency and efficacy.
The global EP market is projected to reach $16B in 2028 with an
11.2% growth rate.3
Forward-looking Statements This press release
contains “forward-looking statements.” Such statements may be
preceded by the words “intends,” “may,” “will,” “plans,” “expects,”
“anticipates,” “projects,” “predicts,” “estimates,” “aims,”
“believes,” “hopes,” “potential” or similar words. Forward-looking
statements are not guarantees of future performance, are based on
certain assumptions and are subject to various known and unknown
risks and uncertainties, many of which are beyond the Company’s
control, and cannot be predicted or quantified and consequently,
actual results may differ materially from those expressed or
implied by such forward-looking statements. Such risks and
uncertainties include, without limitation, risks and uncertainties
associated with (i) the geographic, social and economic impact of
COVID-19 on our ability to conduct our business and raise capital
in the future when needed, (ii) our inability to manufacture our
products and product candidates on a commercial scale on our own,
or in collaboration with third parties; (iii) difficulties in
obtaining financing on commercially reasonable terms; (iv) changes
in the size and nature of our competition; (v) loss of one or more
key executives or scientists; and (vi) difficulties in securing
regulatory approval to market our products and product candidates.
More detailed information about the Company and the risk factors
that may affect the realization of forward-looking statements is
set forth in the Company’s filings with the Securities and Exchange
Commission (SEC), including the Company’s Annual Report on Form
10-K and its Quarterly Reports on Form 10-Q. Investors and security
holders are urged to read these documents free of charge on the
SEC’s website at http://www.sec.gov. The Company assumes no
obligation to publicly update or revise its forward-looking
statements as a result of new information, future events or
otherwise.
1 U.S. Patent Application Nos. 17/240,809 (“Methods, systems and
media for reconstructing bioelectronic lead placement”) and
17/411,955 (“Methods, systems and media for detrending
bioelectronic signals”).
2 "Computational Reconstruction of Electrocardiogram Lead
Placement"
3 Global Market Insights Inc. March 08, 2022
For investor relations:
Andrew Ballou
BioSig Technologies, Inc.
Vice President, Investor Relations
55 Greens Farms
Westport, CT 06880
aballou@biosigtech.com
203-409-5444, x133
For media inquiries:
Katie Freshwater
BioSig Technologies, Inc.
Vice President, Marketing
55 Greens Farms
Westport, CT 06880
kfreshwater@biosigtech.com
203-409-5444, x162
BioSig Technologies (NASDAQ:BSGM)
Historical Stock Chart
From Jun 2024 to Jul 2024
BioSig Technologies (NASDAQ:BSGM)
Historical Stock Chart
From Jul 2023 to Jul 2024